Fitness band maker Whoop says it will not disable its blood pressure tracking tool despite the US FDA's request from July and requests a meeting with the agency
Whoop Inc., the maker of screen-less fitness bands, said it will not disable its blood-pressure tracking tool despite a request from the US Food and Drug Administration.
Context & Ripple Effects
Whoop had recently expanded its screenless wearable line with a medical-grade version of Whoop 5.0, raising the stakes around how its health measurements are presented and governed.
This dispute puts the FDA at the center of Whoop’s move from performance tracking toward more health-oriented features. It matters because the company is choosing to contest the agency’s request while also saying the tool is being updated.
First-order effects
- Whoop will keep its blood-pressure tracking tool available rather than comply with the FDA’s request to disable it, while seeking a meeting with the agency.
- The company must defend the tool’s current use and explain its planned update to regulators and users.
Second-order effects
- The standoff increases regulatory and product-risk scrutiny for Whoop’s health-feature roadmap, including features introduced alongside its medical-grade wearable offering.
- Other wearable makers pursuing health measurements may face greater pressure to distinguish fitness insights from functions that draw FDA intervention.
Third-order effects
- If similar disputes persist, wearable companies will need to build regulatory review and product-change processes into health-feature launches rather than treat them as ordinary software updates.
- The episode points to a less stable boundary between consumer wellness tracking and regulated health functionality; how agencies resolve such cases will shape that boundary.
The trend: Consumer wearables are moving toward clinically consequential health features, making regulatory accountability a product-design constraint rather than a back-office issue.